Sysmex (OTCMKTS:SSMXY) Hits New 12-Month Low – What’s Next?

Sysmex Corporation ADR (OTCMKTS:SSMXY) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $11.31 and last traded at $11.77, with a volume of 4188 shares trading hands. The stock had previously closed at $11.95.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. The Goldman Sachs Group raised Sysmex from a “hold” rating to a “buy” rating in a report on Thursday, October 9th. Zacks Research upgraded Sysmex from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Sysmex presently has a consensus rating of “Moderate Buy”.

Sysmex Stock Down 1.7%

The company has a 50-day moving average of $12.56 and a two-hundred day moving average of $15.51. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.37 and a quick ratio of 2.49. The company has a market capitalization of $7.40 billion, a PE ratio of 23.50 and a beta of 1.16.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.07). Sysmex had a return on equity of 10.20% and a net margin of 9.35%.The company had revenue of $717.09 million during the quarter, compared to the consensus estimate of $807.27 million. Sell-side analysts anticipate that Sysmex Corporation ADR will post 0.57 earnings per share for the current fiscal year.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.